Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Early clinical trials conducted primarily in Japan have shown that TAS-102, an oral agent that combines trifluridine and tipiracil hydrochloride, was effective in the treatment of refractory colorectal cancer. We conducted a phase 3 trial to further assess the efficacy and safety of TAS-102 in a global population of such patients. METHODS: In this double-blind study, we randomly assigned 800 patients, in a 2:1 ratio, to receive TAS-102 or placebo. The primary end point was overall survival. RESULTS: The median overall survival improved from 5.3 months with placebo to 7.1 months with TAS-102, and the hazard ratio for death in the TAS-102 group versus the placebo group was 0.68 (95% confidence interval [CI], 0.58 to 0.81; P<0.001). The most frequently observed clinically significant adverse events associated with TAS-102 were neutropenia, which occurred in 38% of those treated, and leukopenia, which occurred in 21%; 4% of the patients who received TAS-102 had febrile neutropenia, and one death related to TAS-102 was reported. The median time to worsening performance status (a change in Eastern Cooperative Oncology Group performance status [on a scale of 0 to 5, with 0 indicating no symptoms and higher numbers indicating increasing degrees of disability] from 0 or 1 to 2 or more) was 5.7 months with TAS-102 versus 4.0 months with placebo (hazard ratio, 0.66; 95% CI, 0.56 to 0.78; P<0.001). CONCLUSIONS: In patients with refractory colorectal cancer, TAS-102, as compared with placebo, was associated with a significant improvement in overall survival. (Funded by Taiho Oncology-Taiho Pharmaceutical; RECOURSE ClinicalTrials.gov number, NCT01607957.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Third-line treatment options are limited to regorafenib and trifluridine–tipiracil, which have extended median overall survival by less than 2 months over placebo and have been associated with a low response rate (<2%) and median progression-free survival of approximately 2 months, outcomes that highlight the need for new approaches.15,16”
From Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C (2023) · cites this paper as [16]
In the citing paper
“Findings in the monotherapy cohort also compared favorably with the results of a trial of regorafenib (another third-line treatment) involving 505 patients, who had a response of 1.0%, progression-free survival of 1.9 months, and overall survival of 6.4 months.15,16”
From Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C (2023) · cites this paper as [16]
In the citing paper
“As described in the drug package insert, the efficacy and safety have not been established in the primary or secondary treatments [99, 100].”
From Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2018) · cites this paper as [100]
In the citing paper
“Nevertheless, single-agent garsorasib and the combination of garsorasib and cetuximab achieved considerable ORRs of 19.2% and 45.2%, and a trend toward prolonged PFS and OS, as compared with the standard-of-care includes regorafenib and trifluridine/tipiracil, which demonstrated an ORR of 1.0% and 1.6%, respectively.30,31”
In the citing paper
“The phase 3 RECOURCE trial evaluated TAS-102 vs. placebo in metastatic CRC patients refractory to standard chemotherapies [44]. TAS-102 significantly improved mOS to 7.1 months compared to 5.3 months with placebo (HR for death: 0.68, 95% CI 0.58–0.81).”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [44]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Van Cutsem, E., Cervantes, A., Nordlinger, B., & Arnold, D. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu260 · Cited by 1,167
Systemic Therapy for Colorectal Cancer
Meyerhardt, J. A., & Mayer, R. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra040958 · Cited by 1,043
Self-citationSystemic Therapy for Colorectal Cancer
Varghese, A. M. (2019) · DeckerMed CGSO Case-Based Reviews · doi:10.2310/cgso.16189 · Cited by 883
Use of Statins and the Risk of Death in Patients With Prostate Cancer
Yu, O., Eberg, M., Benayoun, S., Aprikian, A., Batist, G., Suissa, S., & Azoulay, L. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.4757 · Cited by 659
Yoshino, T., Mizunuma, N., Yamazaki, K., Nishina, T., Komatsu, Y., Baba, H., Tsuji, A., Yamaguchi, K., Muro, K., Sugimoto, N., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70345-5 · Cited by 326
Self-citationFukushima, M., Suzuki, N., Emura, T., Yano, S., Kazuno, H., Tada, Y., Yamada, Y., & Asao, T. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00253-7 · Cited by 239
Tanaka, N., Sakamoto, K., Okabe, H., Fujioka, A., Yamamura, K., Nakagawa, F., Nagase, H., Yokogawa, T., Oguchi, K., Ishida, K., et al. (2014) · Oncology Reports · doi:10.3892/or.2014.3487 · Cited by 149
Emura, T., Suzuki, N., Yamaguchi, M., Ohshimo, H., & Fukushima, M. (2004) · International Journal of Oncology · doi:10.3892/ijo.25.3.571 · Cited by 120
A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells
Emura, T., Murakami, Y., Nakagawa, F., Fukushima, M., & Kitazato, K. (2004) · International Journal of Molecular Medicine · doi:10.3892/ijmm.13.4.545 · Cited by 104
Research works printed but not linked: 6
- Sobrero A, 2000, Semin Oncol, 27, 72
- Emura T, 2004, Int J Mol Med, 13, 545
- Emura T, 2004, Int J Oncol, 25, 571
- Heidelberger C, 1964, Cancer Res, 24, 1979
- Heidelberger C, 1965, Cancer Res, 25, 377
- Dexter DL, 1972, Cancer Res, 32, 247
Cited by
Items 501–600 of 1,000
Yoshida, M., Takagane, A., Miyake, Y., Shimada, K., Nagata, N., Satō, A., Ogata, Y., Fukunaga, M., Otsuka, K., Takahashi, T., et al. (2016) · Oncology · doi:10.1159/000446372 · Cited by 14
TAS-102 (Lonsurf) for the Treatment of Metastatic Colorectal Cancer. A Concise Review
Zaniboni, A., Bertocchi, P., Barni, S., & Petrelli, F. (2016) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2016.06.003 · Cited by 16
Self-citationYoshino, T., Oki, E., Nozawa, H., Nakajima, T. E., Taniguchi, H., Morita, S., Takenaka, N., Ozawa, D., & Shirao, K. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000411 · Cited by 14
Self-citationGourzoulidis, G., Maniadakis, N., Petrakis, D., Souglakos, J., Pentheroudakis, G. E., & Kourlaba, G. (2018) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2018-0076 · Cited by 14
Dane, F., Özgürdal, K., Yalçın, Ş., Beneklı, M., Aykan, N. F., Yücel, İ., Özkan, M., Evrensel, T., Sevinç, A., Çoşkun, H. Ş., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2018-027665 · Cited by 15
Biweekly Administration of TAS-102 for Neutropenia Prevention in Patients with Colorectal Cancer
Yoshida, Y., Sakamoto, R., Kajitani, R., Munechika, T., Matsumoto, Y., Komono, A., Aisu, N., Kojima, D., KIYOMI, F., & Hasegawa, S. (2018) · Anticancer Research · doi:10.21873/anticanres.12738 · Cited by 14
Fujii, H. (2024) · Journal of Pharmaceutical Health Care and Sciences · doi:10.1186/s40780-024-00403-4 · Cited by 13
Min, S. T., Roohullah, A., Tognela, A., Jalali, A., Lee, M., Wong, R., Shapiro, J. D., Burge, M., Yip, D., Nott, L. M., et al. (2021) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13553 · Cited by 14
Cui, T.-M., Altaf, M., Aldarhami, A., Bazaid, A. S., Saeedi, N. H., Alkayyal, A. A., Alshabrmi, F. M., Ali, F., Aladhadh, M. A., Khan, M. Y., et al. (2023) · Molecules · doi:10.3390/molecules28083634 · Cited by 16
Lee, V., Parkinson, R. M., ZAHURAK, M. L., Cope, L., Cercek, A., Verheul, H. M. W., Gootjes, E. C., Lenz, H. J., Iqbal, S., Jones, P. A., et al. (2024) · International Journal of Cancer · doi:10.1002/ijc.34845 · Cited by 13
Self-citationLentz, R. W., Friedrich, T. J., Blatchford, P. J., Jordan, K. R., Pitts, T. M., Robinson, H. R., Davis, S. L., Kim, S. S., Leal, A. D., Lee, M. R., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0090 · Cited by 13
Javaid, S., Saad, S. M., Zafar, H., Malik, R., Khan, K. M., Choudhary, M. I., & Rahman, A. (2020) · PLoS ONE · doi:10.1371/journal.pone.0227549 · Cited by 13
Biomarkers of Trifluridine-Tipiracil Efficacy
Voutsadakis, I. A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10235568 · Cited by 13
Immune subtypes and neoantigen-related immune evasion in advanced colorectal cancer
Sugawara, T., Miya, F., Ishikawa, T., Lysenko, A., Nishino, J., Kamatani, T., Takemoto, A., Boroevich, K. A., Kakimi, K., Kinugasa, Y., et al. (2022) · iScience · doi:10.1016/j.isci.2022.103740 · Cited by 15
Ciardiello, D., Chiarazzo, C., Famiglietti, V., Damato, A., Pinto, C., Zampino, M. G., Castellano, G., Gervaso, L., Zaniboni, A., Oneda, E., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100567 · Cited by 15
Self-citationFidelman, N. A., Atreya, C. E., Griffith, M. J., Milloy, M. A., Carnevale, J. C., Cinar, P., Venook, A. P., & Loon, K. V. (2022) · BMC Cancer · doi:10.1186/s12885-022-10401-0 · Cited by 13
Taïeb, J., Price, T. J., Vidot, L., Chevallier, B., Wyrwicz, L. S., & Bachet, J. (2023) · BMC Cancer · doi:10.1186/s12885-022-10489-4 · Cited by 13
Signorelli, C., Calegari, M. A., Basso, M., Anghelone, A., Lucchetti, J., Minelli, A., Angotti, L., Zurlo, I. V., Schirripa, M., Chilelli, M. G., et al. (2023) · Current Oncology · doi:10.3390/curroncol30060413 · Cited by 15
2-Arylquinazolin-4(3H)-ones: A novel class of thymidine phosphorylase inhibitors
Javaid, S., Saad, S. M., Perveen, S., Khan, K. M., & Choudhary, M. I. (2015) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2015.10.006 · Cited by 13
Safety and efficacy of nintedanib for the treatment of metastatic colorectal cancer
Martínez, M. C. R., Sánchez, A., & García‐Carbonero, R. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1385762 · Cited by 14
Takahashi, K., Yoshisue, K., Chiba, M., Nakanishi, T., & Tamai, I. (2017) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.2110 · Cited by 14
Lopez, R. I., Castro, J. L., Cedeño, H., Cisneros, D., Corrales, L., González-Herrera, I., Pérez, M. L., Prestol, R., Salinas, R., Soriano-García, J. L., et al. (2018) · ESMO Open · doi:10.1136/esmoopen-2017-000315 · Cited by 14
Morano, F., & Sclafani, F. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.08.006 · Cited by 14
Kasper, S., Kisro, J., Fuchs, M., Müller, C., Schulz‐Abelius, A., Karthaus, M., Rafiyan, M., & Stein, A. (2018) · BMC Cancer · doi:10.1186/s12885-018-5063-5 · Cited by 13
Rothkamm, K., Christiansen, S., Rieckmann, T., Horn, M., Frenzel, T., Brinker, A., Schumacher, U., Stein, A., Petersen, C., & Burdak‐Rothkamm, S. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.08.038 · Cited by 14
A phase 1b expansion study of TAS‐102 with oxaliplatin for refractory metastatic colorectal cancer
Cecchini, M., Kortmansky, J. S., Cui, C., Wei, W., Thumar, J. R., Uboha, N. V., Hafez, N., Lacy, J., Fischbach, N. A., Sabbath, K. D., et al. (2020) · Cancer · doi:10.1002/cncr.33379 · Cited by 13
Li, S., Hu, H., Ding, D., Zhu, Y., & Huang, J. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01627-8 · Cited by 14
Scagliotti, G. V., Nishio, M., Satouchi, M., Valmadre, G., Niho, S., Galetta, D., Cortinovis, D. L., Benedetti, F. M., Yoshihara, E., Makris, L., et al. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.06.023 · Cited by 13
Self-citationYoshino, T., Taieb, J., Kuboki, Y., Pfeiffer, P., Kumar, A., & Hochster, H. S. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221146137 · Cited by 12
Self-citationSuenaga, M., Mashima, T., Kawata, N., Wakatsuki, T., Dan, S., Seimiya, H., & Yamaguchi, K. (2020) · International Journal of Colorectal Disease · doi:10.1007/s00384-020-03748-y · Cited by 15
Pant, S., Dragovich, T., Lieu, C. H., Jimeno, A., Kundranda, M. N., Menter, D. G., Tchaparian, E. H., Chen, Y. C., & Kopetz, S. (2022) · Investigational New Drugs · doi:10.1007/s10637-022-01308-5 · Cited by 12
Cartwright, E., Slater, S., Saffery, C., Tran, A., Turkes, F., Smith, G. A., Aresu, M., Kohoutová, D., Terlizzo, M., Zhitkov, O., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.102971 · Cited by 12
Miguel, C. A.-D., Jiménez-Castro, J., Sanchez-Vegas, A., Díaz-López, S., & Chaves-Conde, M. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104454 · Cited by 14
Tan, R., Wen, M., Yang, W., Zhan, D., Zheng, N., Liu, M., Zhu, F., Chen, X., Wang, M., Yang, S., et al. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02894-2 · Cited by 12
Yoshino, T., Uetake, H., Tsuchihara, K., Shitara, K., Yamazaki, K., Oki, E., Sato, T., Naitoh, T., Komatsu, Y., Kato, T., et al. (2017) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2017.01.001 · Cited by 15
Self-citationYoshino, T., Yamazaki, K., Shinozaki, E., Komatsu, Y., Nishina, T., Baba, H., Tsuji, A., Tsuji, Y., Yamaguchi, K., Sugimoto, N., et al. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.07.009 · Cited by 12
Self-citationDual compartmental targeting of cell cycle and angiogenic kinases in colorectal cancer models
Capasso, A., Pitts, T. M., Klauck, P. J., Bagby, S. M., Westbrook, L. M., Kaplan, J., Soleimani, M., Spreafico, A., Tentler, J. J., Diamond, J. R., et al. (2018) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000673 · Cited by 13
Herbst, C., Miot, J., Moch, S. L., & Ruff, P. (2020) · BMC Health Services Research · doi:10.1186/s12913-020-05112-w · Cited by 14
Chida, K., Kotani, D., Nakamura, Y., Kawazoe, A., Kuboki, Y., Shitara, K., Kojima, T., Taniguchi, H., Watanabe, J., Endo, I., et al. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211009143 · Cited by 14
Self-citationGao, M., Jiang, T., Li, P., Zhang, J., Xu, K., & Ren, T. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106330 · Cited by 12
Encorafenib plus cetuximab for the treatment of BRAF-V600E-mutated metastatic colorectal cancer
Ros, J., Gonzalez, N. S., Baraibar, I., Salvà, F., Tabernero, J. M., & Élez, E. (2022) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848221110644 · Cited by 15
Self-citationMariani, S., Puzzoni, M., Giampieri, R., Ziranu, P., Pusceddu, V., Donisi, C., Persano, M., Pinna, G., Cimbro, E., Parrino, A., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.852583 · Cited by 14
Kuang, C., Tong, J., Ermine, K., Cai, M., Dai, F., Hao, S., Giles, F. J., Huang, Y., Yu, J., & Zhang, L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1018775 · Cited by 12
Izawa, N., Masuishi, T., Takahashi, N., Shoji, H., Yamamoto, Y., Matsumoto, T., Sugiyama, K., Kajiwara, T., Kawakami, K., Aomatsu, N., et al. (2023) · Targeted Oncology · doi:10.1007/s11523-023-00963-9 · Cited by 14
Alfonso, P. G., Feliú, J., García‐Carbonero, R., Grávalos, C., Guillén‐Ponce, C., Sastre, J., & García‐Foncillas, J. (2016) · Clinical & Translational Oncology · doi:10.1007/s12094-016-1499-8 · Cited by 13
Value in Colorectal Cancer Treatment: Where It Is Lacking, and Why
Saltz, L. B. (2016) · The Cancer Journal · doi:10.1097/ppo.0000000000000194 · Cited by 12
Improved chemoradiation treatment using trifluridine in human colorectal cancer cells in vitro
Matsuoka, K., Kobunai, T., Nukatsuka, M., & Takechi, T. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.10.044 · Cited by 12
Matsuoka, K., Nakagawa, F., Tanaka, N., Okabe, H., Matsuo, K., & Takechi, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102915 · Cited by 12
El‐Deiry, W. S., Winer, A., Slifker, M. J., Taylor, S., Adamson, B. J. S., Meropol, N. J., & Ross, E. A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00142 · Cited by 12
Argilés, G., André, T., Hollebecque, A., Calvo, A., Dahan, L., Cervantes, A. M. R., Leger, C., Amellal, N., Fougeray, R., & Tabernero, J. M. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.01.101 · Cited by 12
Self-citationGuadagni, S., Fiorentini, G., Mambrini, A., Masedu, F., Valenti, M., Mackay, A. R., Sarti, D., Ricevuto, E., Clementi, M., Catarci, M., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.26972 · Cited by 12
Shibutani, M., Nagahara, H., Fukuoka, T., Iseki, Y., WANG, E., Okazaki, Y., Kashiwagi, S., Maeda, K., Hirakawa, K., & Ohira, M. (2020) · Anticancer Research · doi:10.21873/anticanres.14415 · Cited by 12
Tuca, A., Gallego, R., Ghanem, I., Gil-Raga, M., & Feliú, J. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9124015 · Cited by 13
Muzellec, L., Bourien, H., & Edeline, J. (2021) · Cancers · doi:10.3390/cancers14010179 · Cited by 13
Chakrabarti, S., Zemla, T., Ahn, D. H., Ou, F., Fruth, B. F., Borad, M. J., Hartgers, M. L., Wessling, J., Walkes, R. L., Alberts, S. R., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0874 · Cited by 12
The oncogenic control of nucleotide synthesis
Vidal-Cruchez, O., & Ben‐Sahra, I. (2026) · Oncogenesis · doi:10.1038/s41389-026-00608-2 · Cited by 18
Bazarbashi, S. N., Alkhatib, R., Aseafan, M., Tuleimat, Y., Abdel-Aziz, N. M., Mahrous, M., Elsamany, S., Elhassan, T. A. M., & Alghamdi, M. (2024) · JCO Global Oncology · doi:10.1200/go.23.00461 · Cited by 13
Metabolism, toxicity and management of fruquintinib: a novel drug for metastatic colorectal cancer
Patell, K., Mears, V., Storandt, M. H., & Mahipal, A. (2024) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2024.2332364 · Cited by 12
Comprehensive review of signaling pathways and therapeutic targets in gastrointestinal cancers
Ji, P., Chen, T., Li, C. R., Zhang, J., Li, X., & Zhu, H. P. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104586 · Cited by 11
Taniguchi, H., Uehara, K., Ishikawa, T., Okochi, O., Akazawa, N., Okuda, H., Hasegawa, H., Shiozawa, M., Kataoka, M., Satake, H., et al. (2025) · Cancers · doi:10.3390/cancers17030399 · Cited by 11
Suzuki, S., Iwaizumi, M., Yamada, H., Sugiyama, T., Hamaya, Y., Furuta, T., Kanaoka, S., Sugimura, H., Miyajima, H., Osawa, S., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22484 · Cited by 11
Auvray, M., Tougeron, D., Auclin, É., Moulin, V., Artru, P., Hautefeuille, V., Hammel, P. R., Lecomte, T., Locher, C., Sickersen, G., et al. (2019) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2019.08.003 · Cited by 11
Wallander, M., Rolander, B., Åvall-Lundqvist, E. H., & Elander, N. O. (2020) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-20-43 · Cited by 11
Yoshino, T., Uetake, H., Funato, Y., Yamaguchi, Y., Koyama, T., Ozawa, D., Tajiri, M., & Muro, K. (2020) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaa243 · Cited by 11
Self-citationIshizaki, T., Mazaki, J., Enomoto, M., Shigoka, M., Kasahara, K., Matsudo, T., Kawakita, H., Nagakawa, Y., Katsumata, K., & Tsuchida, A. (2021) · Anticancer Research · doi:10.21873/anticanres.14988 · Cited by 11
Montés, A. F., Carmona‐Bayonas, A., Jiménez‐Fonseca, P., Rivera, F. V., Lago, N. M., Rúa, M. C., Castiñeiras, A. C., Villarroel, P. G., Gómez, J. D. L. C., Méndez, J. C., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-93732-5 · Cited by 11
Hsu, H., Huang, K.-C., Chen, W.-S., Jiang, J., Yang, S.-H., Wang, H.-S., Chang, S., Lan, Y., Lin, C., Lin, H., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-94968-x · Cited by 12
Ciardiello, D., Famiglietti, V., Napolitano, S., Esposito, L., Normanno, N., Avallone, A., Latiano, T. P., Maiello, E., Pietrantonio, F., Cremolini, C., et al. (2021) · Cancers · doi:10.3390/cancers13225715 · Cited by 11
Suh, K., Carlson, J. J., Xia, F., Williamson, T. E., & Sullivan, S. D. (2022) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2022.21373 · Cited by 11
Precision Medicine in Metastatic Colorectal Cancer: Targeting ERBB2 (HER-2) Oncogene
Torres-Jiménez, J., Esteban-Villarrubia, J., & Ferreiro, R. (2022) · Cancers · doi:10.3390/cancers14153718 · Cited by 12
Future therapeutic strategies in the treatment of extrapulmonary neuroendocrine carcinoma: a review
Robinson, M., Livesey, D., Hubner, R. A., Valle, J. W., & McNamara, M. G. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231156870 · Cited by 11
Ciardiello, D., Napolitano, S., Famiglietti, V., Esposito, L., Falco, V. D., Liello, A. D., Avallone, A., Maiello, E., Pietrantonio, F., Cremolini, C., et al. (2023) · Cancers · doi:10.3390/cancers15072117 · Cited by 13
Treatment Options in Late-Line Colorectal Cancer: Lessons Learned from Recent Randomized Studies
Tarpgaard, L. S., Winther, S. B., & Pfeiffer, P. (2023) · Cancers · doi:10.3390/cancers16010126 · Cited by 13
Coffman, K., Myojin, Y., Monge, C., Xie, C., Hrones, D. M., Wood, B. J., Levy, E. B., Kleiner, D. E., Figg, W. D., Steinberg, S. M., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008079 · Cited by 11
Waheed, M. T., Ruel, N. H., Whelan, R. L., Fakih, M., Fong, Y., DePeralta, D. K., Merchea, A., Sun, V. C.-Y., Krouse, R. S., Dellinger, T. H., et al. (2024) · Annals of Surgical Oncology · doi:10.1245/s10434-024-15980-9 · Cited by 11
Trifluridine/tipiracil in metastatic colorectal cancer: a guide to its use
Lyseng-Williamson, K. A., Burness, C. B., & Duggan, S. T. (2017) · Drugs & Therapy Perspectives · doi:10.1007/s40267-017-0385-y · Cited by 11
Efficacy and safety of TAS-102 in refractory metastatic colorectal cancer: a meta-analysis
Chen, D., Wu, Y., Lin, H., Wang, Y., Li, L., & Zhang, T. (2018) · Cancer Management and Research · doi:10.2147/cmar.s174584 · Cited by 14
Yang, M., Fang, X., Li, J., Xu, D., Xiao, Q., Yu, S., Hu, H., Weng, S., Ding, K., & Yuan, Y. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1529120 · Cited by 11
Real‐world treatment patterns and outcomes in refractory metastatic colorectal cancer
Chiang, C., Choi, C., Lam, K. O., Chan, B., Lee, S. F., Yeung, S., Lau, K. S., Chan, S. Y., Choy, T. S., & Yuen, K.-K. (2019) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13114 · Cited by 12
What Is a Clinically Meaningful Survival Benefit in Refractory Metastatic Colorectal Cancer?
Ko, Y. J., Abdelsalam, M. G. A., Kavan, P., Lim, H. J., Tang, P. A., Vincent, M., Wong, R. P. W., Kish, M., & Gill, S. (2019) · Current Oncology · doi:10.3747/co.26.4753 · Cited by 11
Giuliani, J., & Bonetti, A. V. (2019) · Anticancer Research · doi:10.21873/anticanres.13551 · Cited by 11
Gong, J., Robertson, M. D., Kim, E. J.-H., Fakih, M., Schrock, A. B., Tam, K. W., Burugapalli, B., Monjazeb, A. M., Hendifar, A. E., Hitchins, M. P., et al. (2019) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2019.08.001 · Cited by 11
Kuchel, A., Ahern, E. S., Collins, S., Whitehall, V., Okano, S., Pelecanos, A. M., Wyld, D., Eastgate, M. A., & Burge, M. (2020) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13420 · Cited by 11
Xu, K., He, J., Zhang, J., Liu, T., Yang, F., & Ren, T. (2020) · Bioscience Reports · doi:10.1042/bsr20201725 · Cited by 11
Intraarterial Chemotherapy for Liver Metastases
Connell, L. C., & Kemeny, N. E. (2020) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2020.08.005 · Cited by 12
Chen, X., Qiu, H., Chen, Y.-W., Wang, M., Zhu, P., Pan, S., Deng, Y.-Y., Yang, L., & Chen, Z. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.690515 · Cited by 12
Trifluridine/Tipiracil in the Treatment of Gastric Cancer
Fostea, R. M., & Arkenau, H. (2022) · Future Oncology · doi:10.2217/fon-2021-0754 · Cited by 11
Noia, V. D., Basso, M., Marsico, V. A., Cerchiaro, E., Rossi, S., D’Argento, E., Strippoli, A., Schinzari, G., Iezzi, R., Cassano, A., et al. (2017) · Future Oncology · doi:10.2217/fon-2017-0025 · Cited by 11
A systematic review of salvage therapies in refractory metastatic colorectal cancer
Petrelli, F., Perego, G., Ghidini, A., Ghidini, M., Borgonovo, K., Scolari, C., Nozza, R., Rampulla, V., Costanzo, A., Varricchio, A., et al. (2020) · International Journal of Colorectal Disease · doi:10.1007/s00384-020-03571-5 · Cited by 11
Self-citationSütcüoğlu, O., Yıldırım, H. Ç., Almuradova, E., Günenç, D., & Yalçın, Ş. (2025) · Medicina · doi:10.3390/medicina61071202 · Cited by 10
“Additionally, TAS-102 prolonged the time to worsening performance status compared to placebo, emphasizing its efficacy in delaying disease progression [44].”
Dayanidhi, D. L., Somarelli, J. A., Mantyh, J. B., Rupprecht, G., Roghani, R. S., Vincoff, S., Shin, I., Zhao, Y., Kim, S. Y., McCall, S. J., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.999004 · Cited by 10
Storandt, M. H., Tran, N. H., Ehret, C. J., Hanna, M. S. E., Jochum, J. A., Moynagh, M. R., & Jatoi, A. (2023) · World Journal of Surgical Oncology · doi:10.1186/s12957-023-03058-x · Cited by 10
Švec, J., Onhajzer, J., & Kořínek, V. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104544 · Cited by 10
Bachet, J., de Gramont, A., Raeisi, M., Rakez, M., Goldberg, R. M., Tebbutt, N. C., Cutsem, E. V., Haller, D. G., Hecht, J. R., Mayer, R. J., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-01968 · Cited by 13
Self-citationBoccaccino, A., Cassaniti, M., Rossini, D., Faccani, L., Casadio, C., & Tamberi, S. (2025) · Cancers · doi:10.3390/cancers17203336 · Cited by 13
Ma, J., Yang, Q., & Ling, Y. (2017) · BMC Cancer · doi:10.1186/s12885-017-3133-8 · Cited by 10
Emerging combination therapies for metastatic colorectal cancer – impact of trifluridine/tipiracil
Puthiamadathil, J., & Weinberg, B. A. (2017) · Cancer Management and Research · doi:10.2147/cmar.s113320 · Cited by 11
Camera, S., Telli, T. A., Woff, E., Vandeputte, C., Kehagias, P., Guiot, T., Critchi, G., Wissam, Y., Bregni, G., Trevisi, E., et al. (2020) · Cancers · doi:10.3390/cancers12102752 · Cited by 12
Zou, Y., Liu, S., Wu, J., & Sun, Z. (2021) · World Journal of Surgical Oncology · doi:10.1186/s12957-021-02443-8 · Cited by 10
Lawler, M., Johnston, B., Schaeybroeck, S. V., Salto‐Tellez, M., Wilson, R. H., Dunlop, M. G., & Johnston, P. G. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00074-8 · Cited by 14
Metadata
- Authors
- Mayer, R. J., Van Cutsem, E., Falcone, A., Yoshino, T., Garcia-Carbonero, R., Mizunuma, N., Yamazaki, K., Shimada, Y., Tabernero, J., Komatsu, Y., Sobrero, A., Boucher, E., Peeters, M., Tran, B., Lenz, H.-J., Zaniboni, A., Hochster, H., Cleary, J. M., Prenen, H., Benedetti, F., Mizuguchi, H., Makris, L., Ito, M., & Ohtsu, A.
- Affiliations
- University of Pisa (IT)
- National Cancer Center Hospital East (JP)
- Centre Eugène Marquis (FR)
- The Royal Melbourne Hospital (AU)
- USC Norris Comprehensive Cancer Center (US)
- Yale Cancer Center (US)
- Taiho Oncology (United States) (US)
- Ospedale Policlinico San Martino (IT)
- Antwerp University Hospital (BE)
- University of Southern California (US)
- Fondazione Poliambulanza Istituto Ospedaliero (IT)
- Dana-Farber Cancer Institute (US)
- KU Leuven (BE)
- Taiho Pharmaceutical (Japan) (JP)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-05-14
- Volume
- 372
- Issue
- 20
- Pages
- 1909-1919
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W242040007
- Semantic Scholar
- 3d08304a7bda1c2d5aa4ab9b3aa96bc534c22f58
- Cited by
- 1,431
- References
- 20
- Citations by year
- 2026: 97 · 2025: 136 · 2024: 165 · 2023: 145 · 2022: 150 · 2021: 138 · 2020: 150 · 2019: 112 · 2018: 115 · 2017: 116 · 2016: 79 · 2015: 27
- FWCI
- 49.50
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- trifluridine/tipiracil, trifluridine, tipiracil, metastatic colorectal cancer, refractory colorectal cancer, oral chemotherapy, overall survival, neutropenia, leukopenia, febrile neutropenia, performance status, drug safety
- MeSH terms
- Adenocarcinoma, Adult, Aged, Aged, 80 and over, Double-Blind Method, Drug Combinations, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Pyrrolidines, Thymine, Trifluridine, Uracil, Colorectal Neoplasms, Proportional Hazards Models, Survival Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.